In a Tuesday cabinet meeting, President Trump ratcheted up pressure on drugmakers as HHS Secretary Robert F. Kennedy Jr. said his department is “deep” into MFN negotiations.
The collaboration with the synthetic biology company supports Ottimo’s investigational new drug submission as a potential cancer treatment planned for late 2025.